Investors

Syncona is a leading FTSE250 company focused on investing in and building global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Net assets

£1,394.0m

Fully diluted NAV per share

£2.08

NAV total return

32.5%

Life science portfolio return

62.6%

Capital pool available to invest in life science

£448.3m

% of net assets invested in life science

68.0%

HY2018 Business Catalysts

  • Continued positive sales progress in Blue Earth
  • Data read-outs in seven ongoing clinical trials; two new clinical trials expected to commence
  • New financings, companies and programme initiations